Assessment of Comorbidity and Use of Prescription and Nonprescription Drugs in Patients Above 65 Years Attending Family Medicine Outpatient Clinics

Münevver Kurt, MD, PhD1, Melahat Akdeniz, MD, PhD2, and Ethem Kavukcu, MD, PhD2

Abstract
Background and aim: Aging is often accompanied by chronic diseases, comorbidity, and polypharmacy. Use of prescription/nonprescription drugs, and over-the-counter (OTC) drugs seen frequently in the elderly. The aim of this study was to assess the comorbidity and multimorbidity status and to evaluate the use of prescription and nonprescription drugs in patients aged 65 years. Materials and Methods: In this cross-sectional and descriptive study, statistical analyses were performed using SPSS Version 22.0. Kolmogorov–Smirnov tests were applied based on meeting the assumption of a normal distribution of the data. Other statistical tests used were one-way analysis of variance tests, t tests, Pearson correlation analysis, Chi-square tests, Mann–Whitney U tests, and Spearman correlation analysis. Results: A total of 244 people participated in the study. The multimorbidity rate was 85%. Participants used an average of 4.26 drugs daily. The polypharmacy ratio was 42%. The nonprescription drug usage rate was 20%. Participants used nonprescription drugs most often with the pharmacist’s advice. Conclusion: Multimorbidity, comorbidity, prescription, and nonprescription drug use were very high among elderly patients. Because older people are more susceptible to adverse drug reactions and drug interactions, physicians who provide care to older people should take a comprehensive drug history.

Keywords
aged, multimorbidity, polypharmacy, prescription drug, nonprescription drug

Manuscript received: June 23, 2019; final revision received: August 5, 2019; accepted: August 8, 2019.

Introduction
Elderly people are the most rapidly growing portion of the patient population worldwide. According to the World Health Organization (WHO; 2018), the proportion of the world’s population above 60 years was 12% worldwide in 2015 and is expected to be 22% in 2050. The aging population is the most important demographic change facing many countries around the world. The population of older persons is also increasing rapidly in Turkey. According to 2017 data from the Turkey Statistical Institute (TÜİK; 2017), the ratio of people above 65 years to the total population in Turkey was 8.5%.

Aging is often accompanied by chronic diseases, comorbidity, and polypharmacy. Multimorbidity is defined as the co-occurrence of at least two chronic conditions. Multimorbidity in elderly people has been estimated to range from 55% to 98% depending on data sources (Violan et al., 2014). Multimorbidity inevitably leads to the use of multiple drugs. Because chronic diseases affect different organ systems, more than one drug is prescribed to elderly people who receive health services from different specialization areas for different diseases (Aykın Nadir, 2013; Whitson et al., 2016). The use of several different medications at the same time is defined as polypharmacy (Buffel du Vaure et al., 2016). In studies, the use of five or more drugs is generally accepted as polypharmacy (Buffel du Vaure et al., 2016;
The Gerontological Society of America [GSA], 2013; Hines & Murphy, 2011).

Polypharmacy may lead to an increased risk of inappropriate drug use, drug–drug and drug–disease interactions, and adverse drug reactions to which older adults are more susceptible. Older people are more vulnerable to morbidity and mortality secondary to drug-related harms because of age-related physiological changes and comorbidity of chronic conditions, such as cardiovascular diseases and mental disorders (Buffel du Vaure et al., 2016; GSA, 2013; Hines & Murphy, 2011). It was reported that approximately 30% of hospitalizations in elderly people were caused by adverse drug events (Gören, Demirkapu, Akpınar Acet, Calı, & Gülüçbe İdrizoglu, 2017).

Another common condition in elderly patients is the use of nonprescription drugs, over-the-counter (OTC) drugs (Dhyani, Rohekar, Patil, & Ganachari, 2015; Mangoni & Jackson, 2004; Vilches & Suman, 2004), or complementary and alternative medicine (CAM; Eng, 2008; Moses, 2005). The noncontrolled use of these products may potentially lead to serious health problems in patients. Especially in elderly patients, drugs used without a physician recommendation may lead to several acute and chronic health problems such as drug–drug interactions, increased drug side effects, increased mortality and morbidity, and increased health expenditures (Bower et al., 2011; Gören et al., 2017; Hines & Murphy, 2011; Huntley, Johnson, Purdy, Valderas, & Salisbury, 2012; Olmos et al., 2012; Salisbury, Johnson, Purdy, Valderas, & Montgomery, 2011; Siddiqui, Min, Verma, & Jamshed, 2014). These products are used simultaneously with prescription drugs, may affect pharmacokinetic profiles of these medicines, may increase or decrease their effects, may cause undesirable side effects, and may trigger drug–drug interactions (Huntley et al., 2012; Siddiqui et al., 2014).

Family physicians are the first contact point for elderly patients with comorbid diseases and multiple drug use and offer holistic health care. At each visit, they can evaluate elderly patients for comorbid conditions and control the drugs that they use to prevent adverse drug events and drug interactions (Bower et al., 2011; Marengoni et al., 2011; Olmos et al., 2012; Salisbury et al., 2011).

In this study, we investigated comorbid conditions, prescription or nonprescription drug use, and nondrug treatment methods in patients above 65 years of age who attended two outpatient clinics of the Family Medicine Department in Akdeniz University Hospital in Turkey. Our aim was to assess the comorbidity and multimorbidity status and to evaluate the use of prescription and nonprescription drugs in our own elderly patient population.

Materials and Methods

This study was designed to be cross-sectional and descriptive and was conducted with 240 adults above the age of 65, who attended two outpatient clinics of the Family Medicine Department in Akdeniz University Hospital in Turkey, between January 2016 and June 2016, and who agreed to take part in the study by giving their consent to participate in the study. Data were collected directly from the patients by face-to-face interview technique.

The study was approved by the Ethics Committee of the Clinical Investigations of the Faculty of Medicine of the University of Akdeniz in a scientific and ethical manner with decision numbered 70904504/253. All investigations were conducted according to the principles of the Declaration of Helsinki.

Statistical Methods Used

The size of the sample for this study was calculated as 240 with the OpenEpi Version 3 open source calculator with the reliability level set at 99%, the frequency percentage set at 50%, the confidence interval set at 5%, and the sample error set at 0.05. The data obtained in the study were analyzed with the Statistical Package for Social Sciences for Windows 22 (SPSS Inc., Chicago, IL). Kolmogorov–Smirnov tests were applied to data meeting the assumption of a normality distribution. One-way analysis of variance (ANOVA) tests were used for data meeting the assumption of homogeneity of variance. Pearson correlation analysis and t tests were applied for data with distributions that met parametric assumptions. Chi-square tests (Pearson’s, Yates-adjusted or Fisher’s exact test according to sample size), Mann–Whitney U tests, and Spearman correlation analysis were used in situations where parametric assumptions were not met. In all comparisons, $p < .05$ was considered statistically significant.

Results

A total of 244 elderly people including 140 females (58.0%) and 100 males (42.0%) participated in this study. The mean age of the participants was 71.02 (minimum = 65; maximum = 87; SD = 5.39). The average age of men and women was similar (women = 70.31, men = 72.02).

Fifty-six percent of the participants had a primary education, 15% through high school, and 13% through college. The majority of participants (88%) identified themselves as middle income. Ninety-six percent of the participants lived in urban areas. Almost all participants (99.08%) were covered by health insurance.

Participants had a mean number of chronic illnesses of 3.61 (minimum = 0, maximum = 12; SD = 2.06, median = 3) per patient. Table 1 details the number of chronic diseases. As the age of the participants increased, the number of chronic diseases also increased statistically significantly (Pearson’s correlation coefficient = .216; $p < .001$).

In this study, the rate of multimorbidity was 85%. The multimorbidity rate was 86% in women and 83% in men.
Although the multimorbidity rate in female patients was higher than that in male patients, this difference was not statistically significant ($p > .05$). The distribution of multimorbidity by age group was evaluated. It was determined that 82.4% of patients aged 65 to 74 years, 91.4% of patients aged 75 to 84 years, and 100% of patients aged above 80 years had multimorbidity. Despite the increase in multimorbidity rates with age, the difference between age groups was not statistically significant.

Hypertension was found to be the most common disease (71.7%) in male and female patients. The distribution of diseases by age group is shown in Table 2. Distribution of disease by age group was assessed with individual multipanel Chi-square tests, and statistically significant differences were found between age groups only for the incidence of three diseases (Chronic renal failure [CKF], heart failure [HF] and asthma; $p < .05$).

### Prescription Drugs and Polypharmacy Conditions

The mean number of drugs used by participants daily was 4.26 (minimum = 0, maximum = 15, $SD = 2.82$). This rate was 3.98 for women and 4.65 for men (Table 4).

As the age of participants increased, the average number of medications they used increased. As expected, there was a strong positive correlation between the total number of chronic illnesses and the median number of medications used (Pearson’s correlation coefficient = .80, $p < .001$).

In this study, the rate of polypharmacy was 42% (38% in women and 47% in men). The difference between genders was not statistically significant ($p > .05$). Polypharmacy was evaluated by age group. The polypharmacy rate for 65 to 74 years was 36.4%, for 75 to 84 years was 56.9%, and for 85 years and above was 50%. This difference between age groups was statistically significant as assessed by Chi-square test ($p < .05$).

Without a doctor’s recommendation, the rate of nonprescription medication use was 20% (21% in women and 18% in men). The difference between the two sexes was not statistically significant ($p > .05$). Forty-four percent of the nonprescription medication users were using medications on the advice of a pharmacist, and 34% of the nonprescription medication users were using the medications on the advice of a family member. Although the rate of nonprescription drug usage decreased as age increased, the difference between the age groups was not statistically significant ($p > .05$). The rate of nonprescription medication use in rural areas was 44% and was 36% in urban areas, but this difference was not statistically significant ($p > .05$).

When the relationship between multimorbidity and nonprescription drug use was assessed, 20.1% of participants with multimorbidities and 19.4% of participants without multimorbidities were using nonprescription medications. The difference between the groups was not statistically significant ($p > .05$). The relationship between multimorbidity and nonprescription drug use is shown in Table 5.

Thirty-five percent of participants reported that they used a natural/herbal product. This rate was 40% in women and 28% in men. There was no statistically significant difference between the sexes in terms of natural/herbal use rates ($p > .05$). The Top 3 most common natural/herbal products used by participants were sage tea (22%), linden (18%), and ginger (6%). Natural/herbal products were generally used for flu/cold (21%), relaxation and sedation (18%), health promotion (12%), cough (8%), constipation (7%), arthralgia (4%) prostate disease (4%), and strengthening immunity (2%).

| Disease                                | %     |
|----------------------------------------|-------|
| Hypertension                           | 71.7  |
| Diabetes mellitus                      | 40.0  |
| Hyperlipidemia                         | 31.25 |
| Depression                             | 18.75 |
| Hypothyroidism                         | 17.91 |
| Osteoporosis                           | 16.66 |
| Cancer                                 | 8.75  |
| Heart failure                           | 7.5   |
| Cerebrovascular accident                | 5.4   |
| Chronic kidney failure                  | 5.4   |
| Asthma                                 | 5.0   |
| Chronic obstructive pulmonary disease   | 5.0   |
| Anxiety                                | 4.1   |
| Hyperthyroidism                        | 0.4   |

### Table 1. Details the Number of Chronic Diseases in Participants.

| Number of chronic diseases | Number of participants | Ratio in all participants (%) |
|----------------------------|------------------------|------------------------------|
| 0 disease                  | 14                     | 5.8                          |
| 1 disease                  | 20                     | 8.3                          |
| 2 disease                  | 42                     | 17.5                         |
| 3 disease                  | 46                     | 19.2                         |
| 4 disease                  | 43                     | 17.9                         |
| 5 disease                  | 34                     | 14.2                         |
| 6 disease                  | 20                     | 8.3                          |
| 7 disease                  | 12                     | 5.0                          |
| 8 disease                  | 5                      | 2.1                          |
| 9 disease                  | 3                      | 1.3                          |
| ≥10 disease                | 1                      | 0.4                          |
| Total                      | 240                    | 100.0                        |

### Table 2. The Distribution of Diseases by Age Group.

| Disease                                      | %     |
|----------------------------------------------|-------|
| Hypertension                                | 71.66 |
| Diabetes mellitus                           | 40.00 |
| Hyperlipidemia                              | 31.25 |
| Depression                                  | 18.75 |
| Hypothyroidism                              | 17.91 |
| Osteoporosis                                | 16.66 |
| Cancer                                      | 8.75  |
| Heart failure                               | 7.5   |
| Cerebrovascular accident                     | 5.4   |
| Chronic kidney failure                       | 5.4   |
| Asthma                                      | 5.0   |
| Chronic obstructive pulmonary disease        | 5.0   |
| Anxiety                                     | 4.1   |
| Hyperthyroidialism                          | 0.4   |
Gerontology & Geriatric Medicine

Discussion

Over the past century, life expectancy has increased dramatically (Violan et al., 2014; WHO, 2018). As people get older, their health problems increase. Multimorbidity and polypharmacy are major problems that arise as populations age. Studies have shown that elderly people use many prescription or nonprescription medicines for their health problems and are exposed to the side effects and interactions of these medicines (GSA, 2013; Hines & Murphy, 2011).

In this study, the mean number of chronic illnesses among participants was found to be 3.61. It was found that 94.2% of all participants had at least one chronic disease and 85% had two or more chronic diseases. In the United States, one in four American adults has multimorbidity, and approximately one third of people above 65 years of age have four or more chronic illnesses (Buffel du Vaure et al., 2016). In the United Kingdom, one out of every six people has two or more chronic illnesses (Barnett et al., 2012). In Turkey, in a study conducted by Ellidokuz, 72% of people above 65 years of age had two or more chronic diseases (Ellidokuz, Ellidokuz, Uçku, & Aydın, 2005). Because our study and the above study were conducted in a hospital’s outpatient clinic, the rates of comorbidity in these two studies may be higher than the studies done in the community in other countries.

Multimorbidity rates were 85% in this study. The rate of multimorbidity was 86% in women and 83% in men. In studies conducted in different countries, multimorbidity differed among people above 65 years of age (Prazeres, Santiago, & Simoes, 2015). In a systematic review by Violan et al. (2014) that included a total of 70,057,611 patients from 12 countries, the average rate of multimorbidity in patients older than 65 years in primary care was 95.1%. According to another systematic review published by Marengoni et al. (2011), the rate of multimorbidity in persons 65 years of age and older was 55% to 98%. Barnett et al. (2012) reported that 65% of people above 65 years of age had multimorbidities in a study conducted in Scotland. The multimorbidity rate in our study was approximately close to the vast majority of studies conducted in the world.

Many studies have shown that multimorbidity and the number of chronic illnesses increase with aging (Buffel du Vaure et al., 2016; Lefèvre et al., 2014; Marengoni et al., 2011; Picco et al., 2016; Willadsen et al., 2016). In this study, as the age of participants increased, the total number of chronic diseases also increased statistically significant (Pearson’s correlation coefficient = .216; p < .001).

In general, it is known that the frequency of multimorbidity in women is higher than in men (Agborsangaya, Lau, Lahtinen, Cooke, & Johnson, 2012; Agur, McLean, Hunt, Guthrie, & Mercer, 2016). In this study, the age of participants increased, the total number of chronic diseases also increased statistically significant (Pearson’s correlation coefficient = .216; p < .001).

Another factor associated with multimorbidity is the socioeconomic status of the patients. Studies have shown that the rate of multimorbidity in low-income patients is higher (Agborsangaya et al., 2012; Agur et al., 2016; Kuo & Lai, 2013; Lefèvre et al., 2014; Schafer et al., 2012). In this study, it was also found that as the level of income decreased, the multimorbidity rates increased. The rate of multimorbidity was 85.7% among low-income people, 85.3% among middle-income people, and 76.9% among high-income people.

Table 3. Diseases With Statistically Significant Differences in Distribution by Age Group.

| Disease                | 65-74 years | 75-84 years | ≥85 years | Statistical significance level |
|------------------------|-------------|-------------|-----------|-------------------------------|
| Chronic kidney failure | 6 (3.4%)    | 7 (12.1%)   | 0 (0%)    | p < .05                       |
| Heart failure          | 10 (5.7%)   | 6 (10.3%)   | 2 (33.3%) | p < .05                       |
| Asthma                 | 9 (5.1%)    | 1 (1.7%)    | 2 (33.3%) | p < .01                       |
| Other diseases         |             |             |           | p > .05                       |

Table 4. Number of Drugs Used by Participants.

| Number of drugs used | Number of participants |
|----------------------|-----------------------|
| No drugs             | 20 (8.33)             |
| 1 drugs              | 22 (9.17)             |
| 2 drugs              | 22 (9.17)             |
| 3 drugs              | 42 (17.50)            |
| 4 drugs              | 34 (14.17)            |
| 5 drugs              | 24 (10.00)            |
| 6 drugs              | 29 (12.08)            |
| 7 drugs              | 18 (7.50)             |
| 8 drugs              | 14 (5.83)             |
| 9 drugs              | 3 (1.25)              |
| ≥10 drugs            | 12 (5.00)             |
| Total                | 240 (100.00)          |
between low- and high-income groups were statistically significant ($p < .05$). For this reason, physicians who care for low-income elderly patients should consider multimorbidity to provide better health care.

The most common diseases in elderly people participating in this study were hypertension (71%), diabetes mellitus (40%), hyperlipidemia (31.3%), atherosclerotic cardiovascular disease (25.4%), and depression (18.8%). In a systematic review published by Willadsen and colleagues (2016), a total of 115 studies were evaluated, and the majority of these studies were conducted in a primary care setting. According to this systematic review, the most common diseases in elderly were diabetes mellitus, stroke, cancer, ischemic heart diseases and chronic obstructive pulmonary disease. In the same study, hypertension was considered a risk factor, not a disease, and was reported to be the most common risk factor in patients. In our study, the diseases we identified in elderly people are quite similar to those found in studies conducted in other countries.

In elderly patients with chronic diseases who obtain health care from different specialties, polypharmacy is an important problem. Elderly people may have difficulty remembering all the medicine they use. Therefore, a drug use history in elderly people should be taken very carefully. In this study, after the medication history was taken from the participants, their electronic records were reviewed. In this study, after the medication history was taken from the participants, their electronic records were reviewed. In this study, after the medication history was taken from the participants, their electronic records were reviewed.

Table 5: The Relationship Between Multimorbidity and Nonprescription Drug Use.

| Multimorbidity                  | NO (%) | YES (%) | Total (%) | Statistical significance level (Chi-square test) |
|--------------------------------|--------|---------|-----------|-----------------------------------------------|
| Multimorbidity NO (number of chronic diseases ≤ 1) | 80.6   | 19.4    | 100       | $p > .05$                                     |
| Multimorbidity YES (number of chronic diseases ≥ 2)  | 79.9   | 20.1    | 100       |                                               |
| Total                                      | 80     | 20      | 100       |                                               |

Approximately one third of participants reported using a natural/herbal product. This rate was 39.3% for females and 28% for males. According to a systematic review that Harris et al. conducted in 2012 that included 49 studies from 15 countries, the prevalence of using any CAM within a year in elderly people was on average 32% (Harris, Cooper, Relton, & Thomas, 2012). In Turkey, in a study conducted by Tulunay, Aypak, and Yikilkan (2015), 30% of older adults with chronic diseases used herbal products. The results of these studies were very close to those found in our study (34.6%).

According to previous studies, the most commonly used CAM type was phytotherapy in Turkey (39.41). Phytotherapy is the use of plant-derived medications in the treatment and prevention of disease. The most frequently used conditions for these products were influenza/cold (21%), tension/stress (18%), and health promotion (12%).

**Conclusion**

Because of the increase in the elderly population worldwide, physicians are increasingly providing care to more elderly patients. Managing medications is a considerable
part of providing care to elderly people. Because older people are more susceptible to adverse drug reactions and drug interactions, physicians should receive a comprehensive drug history, review medications to reduce polypharmacy, and if necessary eliminate unnecessary medications to protect the health and prevent adverse drug reactions. In different countries, education, culture and health habits, and access to health services of elderly people are different. These differences may have affected multimorbidity and polypharmacy rates. For this reason, physicians who care elderly patients should consider community features.

Limitations of this study are the small number of participants and it was conducted in a restricted area. More implementation studies in various medical settings where older adults receive care are needed to bring attention to polypharmacy and multimorbidity.

The strength of the study is that it is conducted by direct interviews with elderly patients. In this study, we wanted to draw attention to the fact that elderly people use nonprescription drugs in addition to prescription drugs. We think that more studies on this subject will contribute to the literature.

Declaration of Conflicting Interests
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The authors received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Melahat Akdeniz https://orcid.org/0000-0003-0792-8701

References
Agborsangaya, C. B., Lau, D., Lahtinen, M., Cooke, T., & Johnson, J. A. (2012). Multimorbidity prevalence and patterns across socioeconomic determinants: A cross-sectional survey. BMC Public Health, 12, 201.

Agur, K., McLean, G., Hunt, K., Guthrie, B., & Mercer, S. W. (2016). How does sex influence multimorbidity? Secondary analysis of a large nationally representative dataset. International Journal of Environmental Research and Public Health, 13, 391.

Aykın Nadir, S. (2013). Derleme: Aile Hekimliğinde Komorbidite ve Multimorbiditeyi Anlamak [Understanding Comorbidity & Multimorbidity in Family Practice]. Türk Journal of Family Medicine and Primary Care, 3(3), 35-39.

Bahat, G., Tufan, F., Akin, S., Tufan, A., Erten, N., & Karan, M. A. (2012). Rational drug use in the elderly. Journal of Gerontology and Geriatric Research, 1(1), 104.

Barnett, K., Mercer, S. W., Norbury, M., Watt, G., Wyke, S., & Guthrie, B. (2012). Epidemiology of multimorbidity and implications for health care, research, and medical education: A cross-sectional study. The Lancet, 380, 37-43.

Bower, P., Macdonald, W., Harkness, E., Gask, L., Kendrick, T., Valderas, J. M., . . .Sibbald, B. (2011). Multimorbidity, service organization and clinical decision making in primary care: A qualitative study. Family Practice, 28, 579-587.

Buffel du Vaure, C., Ravaud, P., Baron, G., Barnes, C., Gilberg, S., & Boutron, I. (2016). Potential workload in applying clinical practice guidelines for participants with chronic conditions and multimorbidity: A systematic analysis. BMJ Open, 6, e010119.

Diyani, V., Rohekar, M. A., Patil, S. D., & Ganachari, M. S. (2015). Inappropriate drug use and its consequences in elderly participants: An overview. IOSR Journal of Pharmacy and Biological Sciences, 10(6), 44-49.

Discigili, G., Tekinç, N., Anadol, Z., & Bozkaya, A. O. (2006). Toplum içinde yaşayan ve bakım verilirde olan yaşlıların polifarmasi [Polypharmacy in nursing home and community-dwelling elderly]. Türk Geriatri Dergisi, 9, 117-121.

Ellidokuz, H., Ellidokuz, E., Uçku, R., & Aydin, U. (2005). Kurumda ve evde yaşayan yaşlıların sağlık durumu değerlendirilmesi [Health status assessment of elderly living in the institution and at home]. Sağlık ve Toplum, 15(2), 40-44.

Eng, M. (2008). Potentially inappropriate OTC medications in older adults. US Pharmacist, 33(6), 29-36.

The Gerontological Society of America. (2013). Over-the-counter medication behaviors of older adults. Retrieved from https://www.chpa.org/PDF/2013MedBehaviorOlderAdults.aspx

Gören, Z., Demirkapu, M., Akşınar Acet, G., Call, S., & Gülcebi İdriz Oğlu, M. (2017). Potential drug–drug interactions among prescriptions for elderly participants in primary health care. Turkish Journal of Medical Sciences, 47, 47-54.

Gupta, M., & Agarwal, M. (2013). Understanding medication errors in the elderly. New Zealand Medical Journal, 126, 62-70.

Harris, P. E., Cooper, K. L., Reltion, C., & Thomas, K. J. (2012). Prevalence of complementary and alternative medicine (CAM) use by the general population: A systematic review and update. International Journal of Clinical Practice, 66, 915-916.

Hazra, N. C., Dregan, A., Jackson, S., & Gulliford, M. C. (2016). Drug utilization and inappropriate prescribing in centenarians. Journal of the American Geriatrics Society, 64, 1079-1084.

Hines, L. E., & Murphy, J. E. (2011). Potentially harmful drug–drug interactions in the elderly: A review. American Journal of Geriatric Pharmacotherapy, 9, 364-377.

Huntley, A. L., Johnson, R., Purdy, S., Valderas, J. M., & Salisbury, C. (2012). Measures of multimorbidity and morbidity burden for use in primary care and community settings: A systematic review and guide. Annals of Family Medicine, 10, 134-141.

Institut de recherche et documentation en économie de la santé. (2014). Polyparmacy: Definitions, measurement and stakes involved review of the literature and measurement tests. Retrieved from https://www.irdes.fr/english/issues-in-health-economics/204-polyparmacy_DEFINITIONS_MEASUREMENT_AND_STAKES_INVOLVED.pdf

Kuo, R. N., & Lai, M. S. (2013). The influence of socio-economic status and multimorbidity patterns on healthcare...
costs: A six-year follow-up under a universal healthcare system. *International Journal for Equity in Health*, 12, 69.

Lam, M. P., Cheung, B. M., & Wong, I. C. (2015). Prevalence of potentially inappropriate prescribing among Hong Kong older adults: A comparison of the Beers 2003, Beers 2012, and Screening Tool of Older Persons’s Prescriptions and Screening Tool to Alert doctors to Right Treatment Criteria. *Journal of the American Geriatrics Society*, 63, 1471-1472.

Lefevre, T., d’Ivernois, J. F., De Andrade, V., Crozet, C., Lombrail, P., & Gagnayre, R. (2014). What do we mean by multimorbidity? An analysis of the literature on multimorbidity measures, associated factors, and impact on health services organization. *Revue d’Épidémiologie et de Santé Publique*, 62, 305-314.

Maher, R. L. J., Hanlon, J. T., & Hajjar, E. R. (2014). Clinical consequences of polypharmacy in elderly. *Expert Opinion on Drug Safety*, 13(1), 10-14.

Mangoni, A. A., & Jackson, S. H. (2004). Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications. *British Journal of Clinical Pharmacology*, 57, 6-14.

Marenghi, A., Angleman, S., Melis, R., Mangialasche, F., Karp, A., Garmen, A., ..Fratiglioni, L. (2011). Aging with multimorbidity: A systematic review of the literature. *Ageing Research Reviews*, 10, 430-439.

Moses, G. (2005). Complementary and alternative medicine use in the elderly. *Journal of Pharmacy Practice and Research*, 35, 63-68.

Olmos, L. G., Salvador, C. H., Alberquilla, A., Lora, D., Carmona, M., Sagredo, P. L.,..García-López, F. (2012). Comorbidity patterns in patients with chronic diseases in general practice. *PLoS ONE*, 7(2), e32141.

Picco, L., Achilla, E., Abdin, E., Chong, S. A., Vaingankar, J. A., McCrone, P., .. Subramaniam, M. (2016). Economic burden of multimorbidity among older adults: Impact on healthcare and societal costs. *BMC Health Services Research*, 16, 173-184.

Prazeres, F., Santiago, L. M., & Simoes, J. A. (2015). Defining multimorbidity: From English to Portuguese using a Delphi technique. *BioMed Research International*, 2015, 965025.

Proulx, J., & Hunt, J. (2015). Drug use among seniors on public drug programs in Canada, 2012. *Healthcare Quarterly*, 18(1), 11-13.

Salisbury, C., Johnson, L., Purdy, S., Valderas, J. M., & Montgomery, A. A. (2011). Epidemiology and impact of multimorbidity in primary care: A retrospective cohort study. *British Journal of General Practice, 61*(582), e12-e21.

Sayir, T. Ç., Aslan Karagozlou, S., & Evcik Toprak, D. (2014). Şişli Etfal Eğitim ve Araştırma Hastanesi Aile Hekimliği Polikliniği’ne başvuran 65 yaş üstü hastalarda polifarmasi ve tamamlayıcı tedavi kullanımının değerlendirilmesi [Evaluation of polypharmacy and complementary therapy use in patients ≥65 years, attending to Family Medicine Outpatient Clinic of Şişli Etfal Training and Research Hospital]. *Türkiye Aile Hekimliği Dergisi*, 18(1), 35-41.

Schafer, I., Hansen, H., Schon, G., Hofels, S., Altiner, A., Dahlhaus, A., ..Wiese, B. (2012). The influence of age, gender and socio-economic status on multimorbidity patterns in primary care. First results from the multicare cohort study. *BMC Health Services Research*, 12, 89.

Schnabel, K., Binting, S., Witt, C. M., & Teut, M. (2014). Use of complementary and alternative medicine by older adults: A cross-sectional survey. *BMC Geriatr*, 14, 38.

Siddiqui, M. J., Min, C. S., Verma, R. K., & Jamshed, S. Q. (2014). Role of complementary and alternative medicine in geriatric care: A mini review. *Pharmacognosy Reviews*, 8(16), 81-87.

Tulunay, M., Aypak, C., & Yikilkan, H. (2015). Herbal medicine use among participants with chronic diseases. *Journal of Intercultural Ethnopharmacology*, 4, 217-220.

Turkey Statistical Institute. (2016). *Haber bülteni. İstatistiklerle Yaşlılar*. Retrieved from http://www.tuik.gov.tr/PreHaberBultenleri.do?id=24644

Vilches, A., & Suman, A. (2004). Awareness of over-the-counter drug use by elderly participants. A hospital-based questionnaire survey. *Age and Ageing*, 33, 205-206.

Violan, C., Fouguet-Boreu, Q., Flores-Mateo, G., Salisbury, C., Blom, J., Freitag, M., ..Valderas, J. M. (2014). Prevalence, determinants and patterns of multimorbidity in primary care: A systematic review of observational studies. *PLoS ONE*, 9(7), e102149.

Whitson, H. E., Johnson, K. S., Sloane, R., Cigolle, C. T., Pieper, C. F., Landerman, L., & Hastings, S. N. (2016). Identifying patterns of multimorbidity in older Americans: Application of latent class analysis. *Journal of the American Geriatrics Society*, 64, 1668-1673.

Willadsen, T. G., Bebe, A., Koster-Rasmussen, R., Jarbol, D. E., Guassora, A. D., Waldorff, F. B., ..Olivarius Nde, F. (2016). The role of diseases, risk factors and symptoms in the definition of multimorbidity: A systematic review. *Scandinavian Journal of Primary Health Care*, 34, 112-121.

World Health Organization. (2018). *Ageing and health*. Retrieved from https://www.who.int/news-room/fact-sheets/detail/ageing-and-health